Genmab A/S Files 6-K Report
Ticker: GNMSF · Form: 6-K · Filed: May 28, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | May 28, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, regulatory-update
Related Tickers: GMAB
TL;DR
Genmab filed a 6-K, mostly boilerplate for employee stock plans.
AI Summary
Genmab A/S filed a Form 6-K on May 28, 2024, to report information for the month of May 2024. This filing is incorporated by reference into Genmab's existing S-8 registration statements, which relate to employee stock plans.
Why It Matters
This filing serves as an update for investors and indicates ongoing reporting compliance by Genmab A/S.
Risk Assessment
Risk Level: low — The filing is a routine report and does not contain new material financial or operational information.
Key Players & Entities
- Genmab A/S (company) — Registrant
- May 2024 (date) — Reporting period
- 20240528 (date) — Filing date
- Form 6-K (document) — Filing type
- Form S-8 (document) — Incorporated registration statements
FAQ
What is the purpose of this Form 6-K filing by Genmab A/S?
The Form 6-K is a report of a foreign private issuer for the month of May 2024 and is incorporated by reference into Genmab A/S's registration statements on Form S-8.
When was this Form 6-K filed?
This Form 6-K was filed on May 28, 2024.
What are the registration statements mentioned in the filing?
The filing mentions Genmab A/S's registration statements on Form S-8, specifically File Nos. 333-232693, 333-253519, 333-262970, and 333-277273.
What is the principal executive office address of Genmab A/S?
The address of Genmab A/S's principal executive offices is Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Does this filing indicate any new financial results or material events?
No, this filing is a routine report and does not appear to disclose new financial results or material events; it primarily serves to incorporate information into existing registration statements.
Filing Stats: 236 words · 1 min read · ~1 pages · Grade level 13.8 · Accepted 2024-05-28 11:29:21
Filing Documents
- tmb-20240528x6k.htm (6-K) — 19KB
- tmb-20240528xex99d1.htm (EX-99.1) — 65KB
- tmb-20240528xex99d1a.htm (EX-99.1(A)) — 7547KB
- tmb-20240528xex99d1001.jpg (GRAPHIC) — 5KB
- tmb-20240528xex99d1a001.jpg (GRAPHIC) — 5KB
- 0001558370-24-008655.txt ( ) — 7646KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: MAY 28, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated May 28, 2024: Transactions in Connection with Share Buy-back Program 99.1(a) Appendix Share buyback program – Specification for May 20 – May 24, 2024